Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
https://doi.org/10.21518/2079-701X-2018-4-86-89
Abstract
Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of the problem, we present a clinical case that shows the efficacy of therapy with liraglutide 3.0 mg daily in a patient with obesity, and its effect on metabolic risk factors.
About the Authors
K. A. Komshilova
National Medical Research Centre of Endocrinology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
Moscow
E. A. Troshina
National Medical Research Centre of Endocrinology of the Ministry of Health of Russia
Russian Federation
Russian Federation
Corr. Member of RAS, MD, Prof.
Moscow
References
1. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization, 1998.
2. Bosello O and Zamboni M. Visceral obesity and metabolic syndrome. Obesity reviews? 2000, 1: 47-56.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 2004, 364(9438): 937–52. doi: 10.1016/S0140-6736(04)17018-9.
4. Jensen MD, Ryan MD, Donato SM, et al. Executive summary: Guidelines (2013) for the management of оverweight and obesity in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Published by The Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring), 2014, 22(suppl 2): 5-39.
5. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond), 2013 Feb, 37(2): 322.
6. Dombrowski SU, Knittle K, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ, 2014, 348: 2646.
7. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond), 2013 Nov, 37(11): 1514.
Review
For citations:
Komshilova KA, Troshina EA. Efficacy of liraglutide 3 mig therapy in obesity and associated diseases. Meditsinskiy sovet = Medical Council. 2018;(4):86-89. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-86-89
Views:
769
Email this article 